4-Pyrazolo[4,3-c]pyridin-1-ylaniline | 1330064-72-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-Pyrazolo[4,3-c]pyridin-1-ylaniline
• 英文别名: 4-pyrazolo[4,3-c]pyridin-1-ylaniline
• CAS: 1330064-72-6
• 化学式: C₁₂H₁₀N₄
• 分子量: 210.238
• InChiKey: TTXBGJPUTMZVIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-Pyrazolo[4,3-c]pyridin-1-ylaniline 、 4-氯-3-三氟甲基异氰酸苯酯 以 甲醇 、 二氯甲烷 为溶剂， 以80%的产率得到1-[4-Chloro-3-(trifluoromethyl)phenyl]-3-(4-pyrazolo[4,3-c]pyridin-1-ylphenyl)urea
  参考文献：
  名称：

  Synthesis of indazole based diarylurea derivatives and their antiproliferative activity against tumor cell lines

  摘要：

  New series of indazole based diarylureas were synthesized and their anticancer activity against cancer cells H460, A549, OS-RC-2, HT-29, Lovo, HepG2, Bel-7402, SGC-7901 and MDA-MB-231 were examined. These derivatives of diarylureas, except azaindazole based diarylureas 5f, 51 and 5m, showed superior or similar activity against most of these selected cancer cell lines to the reference compound sorafenib. The effect of substituents on the indazole ring was also investigated. Derivatives with trifluoromenthy or halogen substituents on the indazole ring showed higher activity against the selected cancer cell lines than sorafenib. The acute toxicity assay showed that compounds 5a, 5b and 5i possessed lower toxicity than sorafenib. Compound 5i with 4-(trifluoromenthy)-1H-indazole and 4-(trifluoromenthy) benzene moieties exhibited the most potent anticancer activity. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.02.034
• 作为产物：
  描述：

  1-(4-Nitrophenyl)pyrazolo[4,3-c]pyridine 在 盐酸 、 碳酸氢钠 、 magnesium sulfate 、 tin(ll) chloride 作用下， 以 二氯甲烷 、 水 为溶剂， 生成 4-Pyrazolo[4,3-c]pyridin-1-ylaniline
  参考文献：
  名称：

  Synthesis of indazole based diarylurea derivatives and their antiproliferative activity against tumor cell lines

  摘要：

  New series of indazole based diarylureas were synthesized and their anticancer activity against cancer cells H460, A549, OS-RC-2, HT-29, Lovo, HepG2, Bel-7402, SGC-7901 and MDA-MB-231 were examined. These derivatives of diarylureas, except azaindazole based diarylureas 5f, 51 and 5m, showed superior or similar activity against most of these selected cancer cell lines to the reference compound sorafenib. The effect of substituents on the indazole ring was also investigated. Derivatives with trifluoromenthy or halogen substituents on the indazole ring showed higher activity against the selected cancer cell lines than sorafenib. The acute toxicity assay showed that compounds 5a, 5b and 5i possessed lower toxicity than sorafenib. Compound 5i with 4-(trifluoromenthy)-1H-indazole and 4-(trifluoromenthy) benzene moieties exhibited the most potent anticancer activity. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.02.034

文献信息

• [EN] ANTI-TUMOR MEDICAMENT OF STRUCTURE OF DIARYLUREA OR THIOUREA KIND BASED ON INDAZOLE OR AZA-INDAZOLE<br/>[FR] MÉDICAMENT ANTITUMORAL AYANT UNE STRUCTURE DE TYPE DIARYLURÉE OU THIOURÉE À BASE D'INDAZOLE OU D'AZAINDAZOLE
  申请人：JINAN HAILE PHARMATECH CO LTD

  公开号：WO2011120327A1

  公开（公告）日：2011-10-06

  An anti-tumor medicament, especially an anti-tumor medicament of structure of diarylurea or thiourea kind based on indazole or aza-indazole is disclosed in the present invention. The structure of the medicament is shown as formula (Ia) or (Ib):wherein, Z is N atom or C atom; W is O, S, NH, NOH, NCN and so on; M is O, S, N, CH and so on; n is 1 or 2; Y and R are halogen atom, H, R1, CF3, OCF3, OH, OR2, OCOR3, NH2, NHR4, NR52, NHCOR6, carboxyl, ester, cyano, thiol, alkylthio, sulfonyl, sulfoxide group, sulfonic group, sulfonate group, sulphonylamino, keto, aldehyde group, nitro group, nitroso group. The medicament can be used for treating lung cancer, renal carcinoma, colon cancer, liver cancer, stomach cancer and breast cancer in human.
• Synthesis of indazole based diarylurea derivatives and their antiproliferative activity against tumor cell lines
  作者：Cui-rong Zhao、Rui-qi Wang、Gang Li、Xiao-xia Xue、Chang-jun Sun、Xian-jun Qu、Wen-bao Li

  DOI：10.1016/j.bmcl.2013.02.034

  日期：2013.4

  New series of indazole based diarylureas were synthesized and their anticancer activity against cancer cells H460, A549, OS-RC-2, HT-29, Lovo, HepG2, Bel-7402, SGC-7901 and MDA-MB-231 were examined. These derivatives of diarylureas, except azaindazole based diarylureas 5f, 51 and 5m, showed superior or similar activity against most of these selected cancer cell lines to the reference compound sorafenib. The effect of substituents on the indazole ring was also investigated. Derivatives with trifluoromenthy or halogen substituents on the indazole ring showed higher activity against the selected cancer cell lines than sorafenib. The acute toxicity assay showed that compounds 5a, 5b and 5i possessed lower toxicity than sorafenib. Compound 5i with 4-(trifluoromenthy)-1H-indazole and 4-(trifluoromenthy) benzene moieties exhibited the most potent anticancer activity. (C) 2013 Elsevier Ltd. All rights reserved.